Long-Acting Cabotegravir Plus VRC01LS for Viral Suppression in HIV-1-Infected Adults

Condition:   HIV Infections Interventions:   Drug: Oral Cabotegravir (CAB);   Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs);   Drug: Long-Acting Injectable Cabotegravir (CAB LA);   Biological: VRC01LS;   Drug: Standard of Care (SOC) Oral ART Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2QGfkRB